<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; one</title>
	<atom:link href="http://www.tapanray.in/tag/one/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Stakeholder Sentiment: Back to Square One?</title>
		<link>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-stakeholder-sentiment-back-to-square-one</link>
		<comments>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/#comments</comments>
		<pubDate>Mon, 28 May 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[guru]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximizing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[non-profit]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[socializing]]></category>
		<category><![CDATA[square]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8965</guid>
		<description><![CDATA[Is it fair to push out the core purpose of an important process, or rather a mission, unfairly? Whether we like it or not, it happened that way, over a period of time. Way back on December 01, 1950, George W. &#8230; <a href="http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NHPS: &#8220;One Nation, One Scheme is Enticing&#8221;, But Will It Work?</title>
		<link>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nhps-one-nation-one-scheme-is-enticing-but-will-it-work</link>
		<comments>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/#comments</comments>
		<pubDate>Mon, 12 Mar 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aayog]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Mahatma Jyotiba Phule Jan Aarogya Abhiyan]]></category>
		<category><![CDATA[Modicare]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[National Health Protection Scheme]]></category>
		<category><![CDATA[NHPS]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8903</guid>
		<description><![CDATA[Yet another slogan: “One nation &#8211; One Universal Health Coverage (UHC)” would indeed be enticing for many, including India. Nevertheless, that’s just a hope. Let’s now try to get a message out of what has been recently happening around this &#8230; <a href="http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The R&amp;D Factor: “One of the Great Myths of the Industry&#8221;</title>
		<link>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-rd-factor-one-of-the-great-myths-of-the-industry</link>
		<comments>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/#comments</comments>
		<pubDate>Mon, 25 Mar 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1 billion]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[android]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[Frost]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[global. CEO]]></category>
		<category><![CDATA[greatest]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[myths]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OS]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Sullivan]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Thomson]]></category>
		<category><![CDATA[Tuft]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[vindication]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2085</guid>
		<description><![CDATA[Yes, that is what the global CEO of one of the Pharmaceutical giants of the world commented in a very recent interview with Reuters. Adding further to this comment he said, “US $1 billion price tag for R&#38;D was an &#8230; <a href="http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
